(Press-News.org) BOSTON -- Radiation therapy is used as a treatment for more than half of all cancer patients and can be highly effective at shrinking tumors and killing cancer cells. But radiation treatment can also damage healthy tissue, including tissue in the mouth and gastrointestinal tract. This tissue injury can lead to oral mucositis, esophagitis, and proctitis -- painful and sometimes debilitating tissue damage. It's estimated that these injuries occur in over 200,000 patients in the U.S. each year. In a new paper published in Advanced Science, investigators from Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital and MIT describe efforts to develop a new personalized, 3D-printed device intended to shield patients who are undergoing radiation therapy and prevent radiation-induced toxicity. The work to date has been conducted in preclinical models and uses simulations to predict effects in humans, laying groundwork for clinical trials for patients.
"When we treat patients with radiation, we do our best to minimize the area of healthy tissue that receives radiation and break up treatment into small doses, but it's a fine balance. We want to administer the most dose we can to shrink the tumor without causing damage to healthy tissue," said lead author James Byrne, MD, PhD, a postdoctoral researcher in the Traverso lab at the Brigham and MIT and a senior resident physician in Radiation Oncology at Brigham, MGH, and Dana-Farber Cancer Institute. "Our goal through this project was to find an innovative solution that could offer personalized protection for patients."
Byrne collaborated with a multi-disciplinary team on the work, including experts in radiation oncology, physicists, mechanical engineers, and gastroenterologists.
"It's not uncommon for gastroenterologists to be called in to consult on a case to support a patient who is experiencing side effects of radiation in the esophagus, small intestine or anywhere else in the gastrointestinal tract," said corresponding author C. Giovanni Traverso, MB, BChir, PhD, a gastroenterologist and biomedical engineer in the Division of Gastroenterology at the Brigham and MIT. "A couple of years ago, James and I began brainstorming -- what if we could develop a shield that could help protect a significant portion of normal tissue in the radiation field?"
Byrne and colleagues tested a broad range of materials -- both solid and liquid -- from which to construct the radioprotective shields. The team focused on high atomic number (Z) materials, which can prevent gamma and X-rays from passing through, and other materials to reduce radiation backscatter. Using CT scans from patients, the team created designs unique to individual patients and used 3D-printing to generate them. They tested their shields in rats and pigs. They found that the shields could protect healthy tissue in the mouth and rectum in rats with good feasibility and reproducibility of placement in pigs. In simulations of human patients, the team estimated that the device could reduce radiation to areas in the mouth by 30 percent for head and neck cancer patients, and in the gastrointestinal tract by 15 percent in prostate cancer patients, without reducing radiation dose to the tumor.
The authors note that this work is an initial proof-of-concept study and additional investigations will be needed to translate the devices for use in the clinic. However, their results so far suggest that personalized shields could someday help reduce the risk of radiation toxicity.
"Our results support the feasibility of personalized devices for reducing the side effects of radiation therapy," said Byrne. "This personalized approach could be applicable to a variety of cancers and holds the potential to reduce the burden of radiation injury and toxicity for our patients."
INFORMATION:
Video
Credit: Giancarlo Traverso, GT Reel Productions
Long version (with music):
https://youtu.be/zfINA4gVKkc
Long version (without music):
https://youtu.be/dQK1916DNuA
Short/Social Media Version (00:36):
https://youtu.be/511hQa6frHA
Funding for this work was provided by grants from Joint Center for Radiation Therapy Internal Award, the National Institutes of Health (EB-000244), and Prostate Cancer Foundation Young Investigator Award. Traverso was supported in part by the Karl van Tassel (1925) Career Development Professorship and the Department of Mechanical Engineering, MIT.
Other authors who contributed to this work include Cameron C. Young, Jacqueline N. Chu, Jennifer Pursley, Mu Xian Chen, Adam J. Wentworth, Annie Feng, Ameya R. Kirtane, Kyla A. Remillard, Cindy I. Hancox, Mandar S. Bhagwat, Nicole Machado, Tiffany Hua, Siddartha M. Tamang, Joy E. Collins, Keiko Ishida, Alison Hayward, Sarah Becker, Samantha K. Edgington, Jonathan D. Schoenfeld, William R. Jeck, and Chin Hur.
Paper cited: Byrne, JD et al. "Personalized radiation attenuating materials for gastrointestinal mucosal protection" Advanced Science DOI: 10.1002/advs.202100510
Brigham Health, a global leader in creating a healthier world, consists of Brigham and Women's Hospital, Brigham and Women's Faulkner Hospital, the Brigham and Women's Physicians Organization and many related facilities and programs. With more than 1,000 inpatient beds, approximately 60,000 inpatient stays and 1.7 million outpatient encounters annually, Brigham Health's 1,200 physicians provide expert care in virtually every medical and surgical specialty to patients locally, regionally and around the world. An international leader in basic, clinical and translational research, Brigham Health has nearly 5,000 scientists, including physician-investigators, renowned biomedical researchers and faculty supported by over $700 million in funding. The Brigham's medical preeminence dates back to 1832, and now, with 19,000 employees, that rich history is the foundation for its commitment to research, innovation, and community. Boston-based Brigham and Women's Hospital is a teaching affiliate of Harvard Medical School and dedicated to educating and training the next generation of health care professionals. For more information, resources, and to follow us on social media, please visit brighamandwomens.org.
Bottom Line: When given a choice, most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy, the method most often recommended by health care providers.
Journal in Which the Study was Published: Cancer Prevention Research, a journal of the American Association for Cancer Research
Author: Xuan Zhu, PhD, senior health services analyst at the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
Background: Although colorectal cancer is the second most frequent cause of cancer-related death in the United States, about one-third of eligible American adults have never completed a colorectal cancer screening test, ...
Using the Atacama Large Millimeter/submillimeter Array (ALMA), astronomers found a rotating baby galaxy 1/100th the size of the Milky Way at a time when the Universe was only seven percent of its present age. Thanks to assistance by the gravitational lens effect, the team was able to explore for the first time the nature of small and dark "normal galaxies" in the early Universe, representative of the main population of the first galaxies, which greatly advances our understanding of the initial phase of galaxy evolution.
"Many of the galaxies that existed ...
For elite runners competing in long-distance races, every second counts. So when Nike introduced "advanced shoe technology" in 2017, questions arose about whether the new design would significantly affect performances in professional sports. A new paper published in END ...
Nagoya University researchers and colleagues in Japan have uncovered a molecular pathway that enhances chemotherapy resistance in some pancreatic cancer patients. Targeting an RNA to interrupt its activity could improve patient response to therapy and increase their overall survival.
"Pancreatic cancer is one of the most aggressive human malignancies, with an overall median survival that is less than five months," says cancer biologist Yutaka Kondo of Nagoya University Graduate School of Medicine. "This poor prognosis is partially due to a lack of potent therapeutic ...
Robotics field aims at mimicking what natural biological entities have achieved throughout millennia of evolution - actions like moving, adapting to the environment, or sensing. Beyond traditional rigid robots, the field of soft robotics has recently emerged using compliant, flexible materials capable to adapt to their environment more efficiently than rigid ones. With this goal in mind, scientists have been working for years in the so-called biohybrid robots or biobots, generally composed of muscle tissue, either cardiac or skeletal, and an artificial scaffold, achieving crawling, ...
Vigorous and rapid air exchanges might not always be a good thing when it comes to addressing levels of coronavirus particles in a multiroom building, according to a new modeling study.
The study suggests that, in a multiroom building, rapid air exchanges can spread the virus rapidly from the source room into other rooms at high concentrations. Particle levels spike in adjacent rooms within 30 minutes and can remain elevated for up to approximately 90 minutes.
The findings, published online in final form April 15 in the journal Building and Environment, come from a team of researchers at the U.S. Department of Energy's Pacific Northwest National Laboratory. The team includes building and HVAC experts ...
Diseases continue to be a major threat to coral reef health. For example, a relatively recent outbreak termed stony coral tissue loss disease is an apparently infectious waterborne disease known to affect at least 20 stony coral species. First discovered in 2014 in Miami-Dade County, the disease has since spread throughout the majority of the Florida's Coral Reef and into multiple countries and territories in the Caribbean. Some reefs of the northern section of Florida's Coral Reef are experiencing as much as a 60 percent loss of living coral tissue area.
A new study by researchers at Florida Atlantic University's Harbor ...
INDIANAPOLIS -- A team from Regenstrief Institute leveraged OpenMRS, a global open-source electronic medical record (EMR), to create an emergency EMR for Indianapolis first responders preparing for a possible influx of COVID-19 patients. This process was completed in a week to allow Indianapolis Emergency Medical Services (IEMS) to register patients, collect basic clinical information, and send these encounters to Indiana's health information exchange, a crucial element to help the response to the COVID-19 pandemic.
IEMS asked Regenstrief research scientists for help ...
Invasive Group B Streptococcus (GBS) disease, notably meningitis, during the first days and months of a baby's life can have persistent effects for children and hence their families, according to new research. Published in the Lancet Child & Adolescent Health, the study is the first evidence of long-term effects including after GBS sepsis (infection in the bloodstream).
This large study analysed outcomes for nearly 25,000 children born in Denmark and The Netherlands, between 1997 and 2017. Results show that children who had invasive GBS infection are twice as likely to have neurodevelopmental impairments (NDI) and ...
BOSTON - A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells through a targeted antibody, has been found in a global phase 3 clinical study to nearly double the survival time of patients with refractory metastatic triple-negative breast cancer. The study of the ADC drug sacituzumab govitecan (SG), for which Massachusetts General Hospital (MGH) was a lead clinical research site after serving as the lead site for the pivotal phase 1/2 trial, reported superior outcomes compared to single-agent chemotherapy, the standard for treating metastatic triple-negative breast cancer. The phase 3 results of the study, known as ASCENT, were published in the New England Journal of Medicine.
"Favorable results with SG versus chemotherapy were observed ...
